LinkedInFacebookTwitterRssEmail
(832) 968-8698|sales@avancebio.com

News & Events

20 10, 2025

Technote: Implementing Data Integrity and 21 CFR Part 11 Compliance in NGS Workflows

2025-12-11T18:38:31+00:00

Next-generation sequencing (NGS) technologies are transforming regulated drug development by enabling high-resolution analysis for applications such as gene editing, adventitious agent detection, and sequence confirmation. However, integrating NGS into GMP and GLP workflows introduces significant challenges related to data integrity and compliance with 21 CFR Part 11. These regulations require strict controls over electronic records...

Technote: Implementing Data Integrity and 21 CFR Part 11 Compliance in NGS Workflows2025-12-11T18:38:31+00:00
20 10, 2025

Technote: qPCR or ddPCR for Bioanalysis

2025-12-11T18:38:57+00:00

Dive into the comparison of quantitative PCR (qPCR) and digital droplet PCR (ddPCR), uncovering their strengths, limitations, and optimal applications. Backed by decades of experience, Avance Biosciences offers unparalleled expertise in both qPCR and ddPCR technologies, ensuring accurate results and compliance within regulatory environments. Discover the nuances between these methodologies and learn how to choose the right approach for your bioanalytical challenges...

Technote: qPCR or ddPCR for Bioanalysis2025-12-11T18:38:57+00:00
20 10, 2025

Technote: GUIDE-Seq/iGuide for CRISPR On/Off Target Analysis

2025-12-11T18:39:42+00:00

This guide provides an in-depth look at GUIDE-Seq/iGuide, a key technique for assessing CRISPR-Cas9 on- and off-target effects in gene and cell therapy development. It explains how the method informs the selection of gRNAs, nucleases, and CRISPR conditions to maximize specificity and safety. Readers will also gain insights into the full workflow, from Cas9 cleavage to NGS analysis, supported by Avance Biosciences’ expertise as a licensed GUIDE-Seq service provider...

Technote: GUIDE-Seq/iGuide for CRISPR On/Off Target Analysis2025-12-11T18:39:42+00:00
20 10, 2025

Technote: NGS for Biologics Development Support

2025-12-11T18:40:13+00:00

Explore the power of Next Generation Sequencing (NGS) for biologics development support with our latest whitepaper. Avance Biosciences is at the forefront of NGS testing, offering tailored solutions to support drug development initiatives and GMP manufacturing activities. Delve into real-world case studies, including CRISPR indel amplicon sequencing and insertion site studies, showcasing our expertise in assay development and validation...

Technote: NGS for Biologics Development Support2025-12-11T18:40:13+00:00
20 10, 2025

Technote: Phage Testing of Bacterial Cultures

2025-10-22T20:50:13+00:00

Download our whitepaper on “Phage Testing of Bacterial Cultures” to understand the critical importance of mitigating phage contamination in biotech and pharmaceutical industries. Learn about the lytic and lysogenic life cycles of phages, their role in bacterial biology, and the challenges they pose to the biotech and pharmaceutical industries due to contamination. Phage presence in cultures can significantly skew results, posing challenges in bacterial identification and isolation...

Technote: Phage Testing of Bacterial Cultures2025-10-22T20:50:13+00:00
17 10, 2025

Poster Presentation: Digitally Secure Sequencing – Implementing Part 11 Ready NGS Data Security in a CRO Environment

2025-10-22T20:50:56+00:00

Next- and third-generation sequencing are vital for GMP, GLP, and clinical applications, but data integrity challenges and 21 CFR Part 11 compliance require secure instruments, validated workflows, and robust audit trails...

Poster Presentation: Digitally Secure Sequencing – Implementing Part 11 Ready NGS Data Security in a CRO Environment2025-10-22T20:50:56+00:00
17 10, 2025

Poster Presentation: Genome-wide Mapping of CRISPR-Cas Off-Target Cleavage Sites via GUIDE-Seq

2025-10-22T20:51:05+00:00

Genome editing offers unprecedented precision, but off-target effects remain a key safety concern. GUIDE-Seq provides a high-throughput, genome-wide method to map CRISPR-Cas activity in living cells, enabling researchers to assess specificity and ensure safer gene-editing therapies...

Poster Presentation: Genome-wide Mapping of CRISPR-Cas Off-Target Cleavage Sites via GUIDE-Seq2025-10-22T20:51:05+00:00
1 10, 2025

Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Abeta40 in patients with mild cognitive impairment or very mild Alzheimer’s disease: A randomized, double-blind, placebo-controlled phase 2 study

2025-10-01T00:00:00+00:00

INTRODUCTION: ABvac40 is an investigational active immunotherapy (vaccine) targeting Abeta40. This study assessed the safety and immunogenicity of ABvac40 in patients with amnestic mild cognitive impairment or very mild Alzheimer's disease. METHODS: AB1601 was a multicenter, randomized, double-blind, placebo-controlled phase 2 study. Patients (n = 124) received five monthly injections plus a 10-month booster of [...]

Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Abeta40 in patients with mild cognitive impairment or very mild Alzheimer’s disease: A randomized, double-blind, placebo-controlled phase 2 study2025-10-01T00:00:00+00:00
1 10, 2025

A Fit-for-purpose Strategy for Clinical Immunogenicity Assessment of Multivalent Bispecific Antibodies

2025-10-01T00:00:00+00:00

Bispecific antibodies (BsAbs) have emerged as a promising class of therapeutics to treat complex diseases, offering advantages in dual targeting simultaneously compared to monospecific antibodies. However, BsAbs often require advanced engineering, and the novel formats present challenges for the development of clinical anti-drug antibody (ADA) assays. Immunogenicity evaluation is a required study endpoint during the [...]

A Fit-for-purpose Strategy for Clinical Immunogenicity Assessment of Multivalent Bispecific Antibodies2025-10-01T00:00:00+00:00
Go to Top